OTTAWA, Aug. 6 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or
"the Company") today wishes to provide updated guidance to the market
regarding the anticipated timing of receipt of test results from the National
Cancer Institute ("NCI").
This morning, the Company announced test results of its lead cancer drug
GAP107B8 (formerly PhG-alpha-1) at the Ottawa Hospital Research Institute
("OHRI"). The Company wishes to ensure that the market remains fully aware of
the content and timing of its external testing program previously announced.
Testing of GAP107B8 is also ongoing at the NCI in its 60 cell line human
cancer tumor panel, and the Company is advised to expect test results within
the next two weeks, which remains in accordance with expectations previously
announced. Full results will be released to the public following a short
period of analysis by Company scientists and advisors.
While testing at OHRI was focused on ovarian cancer, the testing at the
NCI is on a wide variety of human cancers, including breast, colorectal, lung,
ovarian, kidney, prostate, leukemia and various central nervous system cancers
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology
company with a core focus on developing novel peptide therapeutics for the
treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to
inhibit the activity of protein kinase C ("PKC"), a cell signalling enzyme
implicated in certain types and stages of cancer. Independent peer-reviewed
research has demonstrated that the overexpression of PKC plays a role in the
development of ovarian cancer. During 2009 the Company embarked on a program
of independent validation of its drug compounds, resulting in testing at OHRI,
the National Cancer Institute (results pending) and other independent
laboratories. For more information on PharmaGap please visit the Company's
website at www.pharmagap.com.
Note: The TSX-Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release. No Securities Commission or other
regulatory authority having jurisdiction over PharmaGap has approved or
disapproved of the information contained herein. This release contains forward
looking statements that may not occur or may change materially.
For further information:
For further information: relating to this Release, please contact:
Robert McInnis, President & CEO, (613) 990-9551, firstname.lastname@example.org